Eupraxia Pharmaceuticals (EPRX) Q3 2026 earnings review
Eupraxia completes esophagus trial enrollment, but freezes its knee drug
Eupraxia Pharmaceuticals, a clinical-stage developer of extended-release injectable drugs, finished enrolling its main esophagus trial while freezing its knee pain program. The net loss more than doubled to $15 million as research costs climbed 145% to fund the larger study. Chief executive Dr. James A. Helliwell confirmed that the 120-patient trial remains on schedule for an interim readout in December, and $126 million in cash and short-term investments funds operations into the second half of 2028.
| Cash and short-term investments | $126.4M down $7.2M from last quarter |
|---|---|
| Net loss | $15.2M $6.4M a year ago |
| Research and development expenses | $10.8M +145% from a year ago |
| Phase 2b RESOLVE interim data outlook | December 2026 120-patient enrollment completed |
⚖️ Verdict: 🟢 Bullish
The story got better because completing patient enrollment removes timing risk ahead of the December readout, and one-year data from the highest dose group showed two of three patients stayed in remission. One caution: management paused development and partnering talks for its Phase 2b knee osteoarthritis drug to protect the pricing of the esophagus treatment, leaving the company reliant on a single clinical asset.
The question now is whether the blinded Phase 2b interim results in December will match the durable symptom and tissue improvements seen in the smaller open-label cohorts. Strong separation from the inactive control would clear the path to a Phase 3 trial and potential international partnerships, whereas weak separation would stall the company's only active clinical program. The December 2026 interim data release will settle it.
🐂 Bull Case
Lead Esophagus Trial Reaches Target Enrollment
Eupraxia develops EP-104GI, an extended-release steroid injected into the esophagus wall to treat eosinophilic esophagitis (EoE), an inflammatory disease that makes swallowing painful. Chief executive Dr. James A. Helliwell said, "We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December".
On October 15, the biotechnology group completed its target enrollment of 120 adult patients in the blinded, placebo-controlled Phase 2b study. The trial tests 120-milligram and 160-milligram doses against an inactive liquid control across up to 25 global sites. Completing enrollment removes recruitment delays ahead of the December readout, which will guide the design of a Phase 3 trial required for United States regulatory approval.
What to watch: the Phase 2b interim analysis in December 2026. Clear improvements in esophageal tissue health and swallowing symptoms over the inactive control would support moving EP-104GI into a final Phase 3 registration study.
One-Year Data Shows Lasting Patient Relief
Before starting the blinded Phase 2b study, Eupraxia tested rising doses of EP-104GI in an open-label Phase 1b/2a study where doctors and patients knew the dose given. Management wants to show that a single procedure provides relief for up to a year.
In September, the Vancouver-based developer reported 52-week results from Cohort 9, its highest dose group receiving 160 milligrams across 20 injection sites. Two of the three patients stayed in clinical remission at one year, and Helliwell noted "64% of patients remaining in clinical remission over this 52-week period" across the long-term cohorts. In Cohorts 7 through 9, the share of patients with moderate-to-severe swallowing pain fell from 62% to 25% through week 52.
What to watch: additional long-term data from the Phase 1b/2a cohorts over the coming months. Sustained tissue healing at the 120-milligram and 160-milligram doses would strengthen the case for once-a-year dosing.
Cash Reserves Fund Operations Into Late 2028
Clinical-stage drug developers without commercial sales depend on cash reserves to complete multi-year trials. Eupraxia ended September with $126.4 million in cash and short-term investments, by our math, down $7.2 million from June.
The company used $11.3 million of cash in operations during the third quarter, by our math, while option and warrant exercises brought in $4.2 million. Following its $58.6 million net public offering in February and $21.6 million from warrant and option exercises over the first nine months, the drug maker has not yet touched the $20 million of February proceeds earmarked for Phase 3 and new gastrointestinal trials.
What to watch: quarterly operating cash burn as Phase 3 manufacturing and trial preparation begin in 2027. Keeping quarterly cash use near the current $11 million to $13 million pace will preserve the runway into the second half of 2028.
🐻 Bear Case
Pricing Risk Freezes the Knee Pain Drug
Eupraxia has long presented itself as a two-program company developing EP-104GI for the esophagus and EP-104IAR for knee osteoarthritis pain, which completed a 318-patient Phase 2b trial in 2023. Earlier filings stated an intention to evaluate funding and partnership opportunities to advance the knee program into Phase 3.
Instead, management completed a strategic evaluation and decided to "pause the development and partnering discussions with EP-104IAR until we determine that the risk can be adequately addressed". Because both drugs use the same active steroid core, the company cited risks to EP-104GI's commercial opportunity "with respect to cross over utilization" and pricing differences. Direct spending on the knee drug totaled just $44,331 this quarter, leaving the business reliant on a single active clinical asset.
What to watch: whether management finds a formulation or commercial structure that separates the two products. Without a solution, the knee osteoarthritis asset cannot generate partner upfront payments to help fund the Phase 3 esophagus trial.
Esophagus Trial And Stock Grants Double Losses
Doubling the size of the Phase 2b RESOLVE study and expanding the executive team drove total operating expenses up 135% from a year ago to $16.2 million, by our math. Research and development spending dropped 15% from the second quarter as initial manufacturing work eased, but clinical trial execution and overhead stayed elevated.
- Clinical trial expenses: $4.34 million, up 314% from $1.05 million a year ago
- Manufacturing and analytical costs: $1.82 million, up 136% from a year ago
- Research and development salaries and benefits: $2.20 million, up 113% from a year ago
- Total share-based compensation: $2.13 million, up 378% from $0.45 million a year ago
Higher stock option and restricted share unit grants pushed general and administrative expenses up 117% from a year ago to $5.34 million. The company also carries $8.03 million in unrecognized stock compensation that will flow through expenses over roughly the next two and a half years, by our math.
What to watch: research and development spending in the first half of 2027. Management warned that completing Phase 3 development for EP-104GI will require additional capital beyond existing reserves.
👓 Other Themes
Lab Move And Buyout Complete Hub Shift
Eupraxia moved its operations from Victoria to "a two-hub organization based out of Vancouver and Seattle", adding leased spaces in Vancouver and Kirkland, Washington. Chief scientific and operating officer Amanda Malone stepped down during the move, while Dr. Alex Therien took over research and development. On September 9, Malone exchanged her 5% subsidiary stake for 562,500 common shares worth $4.55 million, giving the company full ownership of Eupraxia Pharma Inc.
US Dollar Holdings Create Currency Swings
Although Eupraxia reports in US dollars, its functional currency is the Canadian dollar, and it does not hedge foreign exchange risk. At quarter end, the company held $114.8 million of its cash and short-term investments in US dollars against $2.67 million in US dollar liabilities, by our math. Exchange rate moves caused a $0.31 million foreign exchange loss in the third quarter, compared with a $2.25 million gain in the second quarter.
💲 Other KPIs
Weighted average basic and diluted shares, which include 1.43 million pre-funded warrants, rose 83.1% from 36.92 million a year ago. The increase reflects 14.64 million shares issued in the September 2025 offering, 7.61 million shares and 1.43 million pre-funded warrants in February 2026, and 5.83 million warrants exercised during the first nine months of 2026.
Short-term bills and accrued expenses climbed 81.9% from $5.55 million at the end of December 2025, and rose from $7.16 million in March. Research and development accruals drove the increase, jumping 143.6% since year-end to $7.21 million as clinical trial activity expanded. Higher unpaid accruals reduced operating cash burn by $4.67 million over the first nine months.
🔮 Guidance
Unchanged. Management narrowed the expected release window for interim data from the 120-patient blinded Phase 2b trial in eosinophilic esophagitis to December 2026, within its prior fourth-quarter target. Completing target enrollment in mid-October keeps the readout on schedule.
Unchanged. The biotechnology group still expects its $126.4 million in cash and short-term investments to fund planned operations into the second half of 2028. At the third-quarter operating cash burn of $11.3 million, by our math, existing liquidity covers roughly 11 quarters of spending before Phase 3 expansion costs.
Unchanged. Eupraxia maintains its goal of adding two new product candidates using its polymer delivery platform over the next 24 months. Preclinical spending rose 26.7% from a year ago to $1.17 million in the third quarter as the team screened candidate drugs.
❓ Key Questions
How many patients are included in the December interim readout?
Eupraxia completed enrollment of all 120 patients in mid-October and plans to report interim Phase 2b data in December. Management has not disclosed how many patients will have completed the 12-week biopsy assessment in time for that December cut-off.
How can Eupraxia resolve the knee drug pricing conflict?
Management paused partnering talks for EP-104IAR because it uses the same steroid core as EP-104GI and could undercut pricing or cause cross-over use. Investors need to know whether unlocking the knee asset requires reformulating the drug or waiting until EP-104GI is priced.
How much additional capital will the Phase 3 trial require?
The company has allocated $8 million from its February offering toward Phase 3 development of EP-104GI, but states that completing Phase 3 will require further capital. Management has not yet estimated the total cost or patient size of the registration program.
When will preferred shareholders convert or trigger dividends?
Only 60,000 of the 8.36 million convertible preferred shares converted during the first nine months of 2026. If the stock does not meet mandatory conversion volume and price thresholds by October 31, 2027, unconverted shares will begin accruing 6% stock or 8% cash annual dividends.